A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Recruiting · NCT07280013 · Registry updated 2026-08-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects | Bites and Stings, Blood Protein Disorders, Chemically-Induced Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, injury, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, poisoning, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 | 2026-08-12 | NCT07280013 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| C4 Therapeutics, Inc. | 3 |
20 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.